Header Logo

Connection

Ajaypal Singh to Renal Insufficiency, Chronic

Back to Details
This is a "connection" page, showing publications Ajaypal Singh has written about Renal Insufficiency, Chronic.
Ajaypal Singh
Connection Strength
14.405
Renal Insufficiency, Chronic
  1. Introduction: A Multi-Pronged Approach to CKD Associated With Type 2 Diabetes. Semin Nephrol. 2023 05; 43(3):151444.
    View in: PubMed
    Score: 0.832
  2. Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrol Dial Transplant. 2023 07 31; 38(8):1890-1897.
    View in: PubMed
    Score: 0.816
  3. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jun 15; 388(24):2301.
    View in: PubMed
    Score: 0.809
  4. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
    View in: PubMed
    Score: 0.773
  5. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
    View in: PubMed
    Score: 0.753
  6. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972.
    View in: PubMed
    Score: 0.748
  7. Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO. Am J Nephrol. 2022; 53(5):361-365.
    View in: PubMed
    Score: 0.747
  8. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
    View in: PubMed
    Score: 0.724
  9. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
    View in: PubMed
    Score: 0.724
  10. Occupational risk factors for chronic kidney disease in Andhra Pradesh: 'Uddanam Nephropathy'. Ren Fail. 2020 Nov; 42(1):1032-1041.
    View in: PubMed
    Score: 0.675
  11. Multiparametric Cardiac Magnetic Resonance for Chronic Kidney Disease: Mapping the Footprints of a "Silent Killer"? JACC Cardiovasc Imaging. 2020 11; 13(11):2368-2370.
    View in: PubMed
    Score: 0.675
  12. Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019 11; 28(6):600-606.
    View in: PubMed
    Score: 0.630
  13. Predictors of renal replacement therapy and mortality in children with chronic kidney disease. Saudi Med J. 2015 Jan; 36(1):32-9.
    View in: PubMed
    Score: 0.450
  14. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem. Semin Dial. 2013 Sep-Oct; 26(5):531-4.
    View in: PubMed
    Score: 0.405
  15. Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2013 May 28; 14:114.
    View in: PubMed
    Score: 0.403
  16. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013 Mar; 22(2):198-203.
    View in: PubMed
    Score: 0.397
  17. Chronic kidney disease in the Arab world: a call for action. Nephron Clin Pract. 2012; 121(3-4):c120-3.
    View in: PubMed
    Score: 0.390
  18. Anaemia: Does the KDIGO guideline move the needle in CKD anaemia? Nat Rev Nephrol. 2012 Nov; 8(11):616-8.
    View in: PubMed
    Score: 0.385
  19. Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents. Clin Appl Thromb Hemost. 2012 Sep; 18(5):453-61.
    View in: PubMed
    Score: 0.373
  20. Anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2008 Jan; 3(1):3-6.
    View in: PubMed
    Score: 0.276
  21. Does correction of anemia slow the progression of chronic kidney disease? Nat Clin Pract Nephrol. 2007 Dec; 3(12):638-9.
    View in: PubMed
    Score: 0.273
  22. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16; 355(20):2085-98.
    View in: PubMed
    Score: 0.256
  23. The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney Int. 2023 06; 103(6):1180-1192.
    View in: PubMed
    Score: 0.198
  24. Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply. N Engl J Med. 2022 12 29; 387(26):2482-2485.
    View in: PubMed
    Score: 0.196
  25. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 09; 17(9):1325-1336.
    View in: PubMed
    Score: 0.190
  26. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019 05; 21(5):1199-1208.
    View in: PubMed
    Score: 0.150
  27. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.
    View in: PubMed
    Score: 0.148
  28. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol. 2017; 46(6):488-497.
    View in: PubMed
    Score: 0.138
  29. BP in Dialysis: Results of a Pilot Study. J Am Soc Nephrol. 2018 01; 29(1):307-316.
    View in: PubMed
    Score: 0.138
  30. Prevalence of Hyperparathyroidism, Mineral and Bone Disorders in Children with Advanced Chronic Kidney Disease. Indian J Pediatr. 2016 May; 83(5):420-5.
    View in: PubMed
    Score: 0.121
  31. Cause of Death in Patients With Diabetic CKD Enrolled in the?Trial to Reduce Cardiovascular Events With Aranesp Therapy?(TREAT). Am J Kidney Dis. 2015 Sep; 66(3):429-40.
    View in: PubMed
    Score: 0.115
  32. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.
    View in: PubMed
    Score: 0.101
  33. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46.
    View in: PubMed
    Score: 0.097
  34. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep; 60(3):390-401.
    View in: PubMed
    Score: 0.093
  35. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
    View in: PubMed
    Score: 0.091
  36. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32.
    View in: PubMed
    Score: 0.079
  37. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type?2 Diabetic Patients With CKD. Am J Kidney Dis. 2017 Oct; 70(4):522-531.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.